The use of Dermacell® Allograft in a diabetic patient with critical limb ischemia

Vangelis G Alexiou 1, Stylianos G. Koutsias 1 and Bertasi Giampietro 2, *

1 Vascular Surgery Unit, Department of Surgery, Ioannina University Hospital, Ioannina, Greece.
2 Biotechnology Dept., University of Padua, Italy.
 
Case Study
Magna Scientia Advanced Biology and Pharmacy, 2022, 06(01), 033–035
Article DOI: 10.30574/msabp.2022.6.1.0068
Publication history: 
Received on 24 April 2022; revised on 28 May 2022; accepted on 30 May 2022
 
Abstract: 
Diabetes is a group of metabolic disorders characterized by poor insulin secretion or impaired insulin function both leading to hyperglycemia. One of the long-term complications of this disease process is neuropathy. Neuropathy, particularly in the extremities, leads to poor sensation, which contributes to the occurrence of ulcers typically observed on the feet of diabetic patients. Current treatments for diabetic ulcers include wound dressing, hyperbaric oxygen therapy, negative pressure therapy, and, in advanced cases, amputation of the limb.
 
Keywords: 
Wound Healing; Diabetes; Chronic Wounds; Skin Substitutes; Skin Dressings; Matrices; ADM; Dermacell.
 
Full text article in PDF: